JP2007512327A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007512327A5 JP2007512327A5 JP2006541192A JP2006541192A JP2007512327A5 JP 2007512327 A5 JP2007512327 A5 JP 2007512327A5 JP 2006541192 A JP2006541192 A JP 2006541192A JP 2006541192 A JP2006541192 A JP 2006541192A JP 2007512327 A5 JP2007512327 A5 JP 2007512327A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- nhc
- nme
- tbu
- ipr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 3-methyl-3-hydroxypentyl Chemical group 0.000 claims 220
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 105
- 125000000217 alkyl group Chemical group 0.000 claims 60
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 51
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 27
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 claims 24
- HNJBEVLQSNELDL-UHFFFAOYSA-N gamma-butyrolactam Natural products O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 15
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims 12
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- 239000000651 prodrug Chemical class 0.000 claims 9
- 229940002612 prodrug Drugs 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical group C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 6
- 125000001475 halogen functional group Chemical group 0.000 claims 6
- 125000005647 linker group Chemical group 0.000 claims 6
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 208000001132 Osteoporosis Diseases 0.000 claims 5
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 5
- 201000004681 Psoriasis Diseases 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 102000009310 vitamin D receptors Human genes 0.000 claims 4
- 108050000156 vitamin D receptors Proteins 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000010392 Bone Fractures Diseases 0.000 claims 2
- 241000219198 Brassica Species 0.000 claims 2
- 235000003351 Brassica cretica Nutrition 0.000 claims 2
- 235000003343 Brassica rupestris Nutrition 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 208000037147 Hypercalcaemia Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 206010047642 Vitiligo Diseases 0.000 claims 2
- 206010000496 acne Diseases 0.000 claims 2
- 208000009621 actinic keratosis Diseases 0.000 claims 2
- 231100000360 alopecia Toxicity 0.000 claims 2
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000005779 cell damage Effects 0.000 claims 2
- 208000037887 cell injury Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000003628 erosive effect Effects 0.000 claims 2
- 239000007789 gas Substances 0.000 claims 2
- 230000000148 hypercalcaemia Effects 0.000 claims 2
- 208000030915 hypercalcemia disease Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 238000012423 maintenance Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 235000010460 mustard Nutrition 0.000 claims 2
- 208000005368 osteomalacia Diseases 0.000 claims 2
- 230000007170 pathology Effects 0.000 claims 2
- 229940075993 receptor modulator Drugs 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 229940122361 Bisphosphonate Drugs 0.000 claims 1
- 102000055006 Calcitonin Human genes 0.000 claims 1
- 108060001064 Calcitonin Proteins 0.000 claims 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims 1
- 206010017076 Fracture Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 239000003098 androgen Substances 0.000 claims 1
- 230000000919 anti-host Effects 0.000 claims 1
- 150000004663 bisphosphonates Chemical class 0.000 claims 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 1
- 229960004015 calcitonin Drugs 0.000 claims 1
- 229940069978 calcium supplement Drugs 0.000 claims 1
- 239000011280 coal tar Substances 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 230000005484 gravity Effects 0.000 claims 1
- 208000014617 hemorrhoid Diseases 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 150000004702 methyl esters Chemical class 0.000 claims 1
- 230000011164 ossification Effects 0.000 claims 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 229960004889 salicylic acid Drugs 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000003451 thiazide diuretic agent Substances 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
- QRHZUNBGGBTEBL-UHFFFAOYSA-N CC(NS(C)(=O)=O)=O Chemical compound CC(NS(C)(=O)=O)=O QRHZUNBGGBTEBL-UHFFFAOYSA-N 0.000 description 1
- SGHKHAUOKCTXIS-UHFFFAOYSA-N CCC(CC)(c([o]c1c2)cc1ccc2C(O)=O)c(cc1)cc(C)c1OCC(C(C)(C)C)O Chemical compound CCC(CC)(c([o]c1c2)cc1ccc2C(O)=O)c(cc1)cc(C)c1OCC(C(C)(C)C)O SGHKHAUOKCTXIS-UHFFFAOYSA-N 0.000 description 1
- RXOCBXGOWUICIU-UHFFFAOYSA-N CCC(CC)(c(cc1)cc2c1[o]c(C(NCC(O)=O)=O)c2C)c(cc1)cc(C)c1OCC(C(C)(C)C)O Chemical compound CCC(CC)(c(cc1)cc2c1[o]c(C(NCC(O)=O)=O)c2C)c(cc1)cc(C)c1OCC(C(C)(C)C)O RXOCBXGOWUICIU-UHFFFAOYSA-N 0.000 description 1
- CGWWIOPSHDEWFE-UHFFFAOYSA-N CCC(CC)(c(cc1)cc2c1[o]c(C(O)=O)c2)c(cc1)cc(C)c1OCC(CCCC1(C)C)C1=O Chemical compound CCC(CC)(c(cc1)cc2c1[o]c(C(O)=O)c2)c(cc1)cc(C)c1OCC(CCCC1(C)C)C1=O CGWWIOPSHDEWFE-UHFFFAOYSA-N 0.000 description 1
- GVVJORUGKABQEP-UHFFFAOYSA-N CCC(CC)(c(cc1C)ccc1OCC(C(C)(C)C)O)c(cc1C)cc2c1[o]c(C(N(C)CC(O)=O)=O)c2 Chemical compound CCC(CC)(c(cc1C)ccc1OCC(C(C)(C)C)O)c(cc1C)cc2c1[o]c(C(N(C)CC(O)=O)=O)c2 GVVJORUGKABQEP-UHFFFAOYSA-N 0.000 description 1
- AMAIRBUNPJLPFK-UHFFFAOYSA-N CCC(CC)(c(cc1C)ccc1OCC1(C(C)(C)C)OCCO1)c(cc1C)cc2c1[o]c(C(O)=O)c2 Chemical compound CCC(CC)(c(cc1C)ccc1OCC1(C(C)(C)C)OCCO1)c(cc1C)cc2c1[o]c(C(O)=O)c2 AMAIRBUNPJLPFK-UHFFFAOYSA-N 0.000 description 1
- XIMYSUSOAXYXGV-UHFFFAOYSA-N CCC(CC)(c1cc(cc(cc2)C(N(C)C)=O)c2[o]1)c(cc1C)ccc1OCC(C(C)(C)C)O Chemical compound CCC(CC)(c1cc(cc(cc2)C(N(C)C)=O)c2[o]1)c(cc1C)ccc1OCC(C(C)(C)C)O XIMYSUSOAXYXGV-UHFFFAOYSA-N 0.000 description 1
- PVIKVQSWXXTNRC-RUZDIDTESA-N CCC(CC)(c1cc(cc(cc2)C(N(C)CC(O)=O)=O)c2[o]1)c(cc1)cc(C)c1OC[C@H](C(C)(C)C)O Chemical compound CCC(CC)(c1cc(cc(cc2)C(N(C)CC(O)=O)=O)c2[o]1)c(cc1)cc(C)c1OC[C@H](C(C)(C)C)O PVIKVQSWXXTNRC-RUZDIDTESA-N 0.000 description 1
- WQGVAVSCVBBRGR-UHFFFAOYSA-N CCC(CC)(c1cc(cc(cc2)C(N/C(/N=N)=N/N)=O)c2[o]1)c(cc1)cc(C)c1OCC(C(C)(C)C)=O Chemical compound CCC(CC)(c1cc(cc(cc2)C(N/C(/N=N)=N/N)=O)c2[o]1)c(cc1)cc(C)c1OCC(C(C)(C)C)=O WQGVAVSCVBBRGR-UHFFFAOYSA-N 0.000 description 1
- SLDPYBXZIJTGKN-UHFFFAOYSA-N CCC(CC)(c1cc(ccc(C(N(C)CC(O)=O)=O)c2)c2[o]1)c(cc1C)ccc1OCC(C(C)(C)C)O Chemical compound CCC(CC)(c1cc(ccc(C(N(C)CC(O)=O)=O)c2)c2[o]1)c(cc1C)ccc1OCC(C(C)(C)C)O SLDPYBXZIJTGKN-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52390503P | 2003-11-20 | 2003-11-20 | |
| US60/523,905 | 2003-11-20 | ||
| PCT/US2004/035529 WO2005051938A1 (en) | 2003-11-20 | 2004-11-16 | Vitamin d receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007512327A JP2007512327A (ja) | 2007-05-17 |
| JP2007512327A5 true JP2007512327A5 (https=) | 2007-12-06 |
| JP4717005B2 JP4717005B2 (ja) | 2011-07-06 |
Family
ID=34632843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006541192A Expired - Fee Related JP4717005B2 (ja) | 2003-11-20 | 2004-11-16 | ビタミンｄ受容体モジュレータ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7579488B2 (https=) |
| EP (1) | EP1687289A1 (https=) |
| JP (1) | JP4717005B2 (https=) |
| CA (1) | CA2544857A1 (https=) |
| WO (1) | WO2005051938A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1511740T1 (sl) * | 2002-05-29 | 2009-12-31 | Lilly Co Eli | Modulatorji vitamin d receptorja tipa fenil-tiofen |
| DE60326082D1 (de) | 2002-11-22 | 2009-03-19 | Lilly Co Eli | Modulatoren von vitamin d rezeptoren |
| WO2005051936A1 (en) | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Phenyl-furan compounds as vitamin d receptor modulators |
| ES2291981T3 (es) * | 2003-11-20 | 2008-03-01 | Eli Lilly And Company | Moduladores del receptor de la vitamina d. |
| US7595345B2 (en) | 2003-11-20 | 2009-09-29 | Eli Lilly And Company | Vitamin D receptor modulators |
| CA2544857A1 (en) | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Vitamin d receptor modulators |
| WO2005051898A2 (en) | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Vitamin d receptor modulators |
| CN1980891B (zh) * | 2004-05-03 | 2011-03-09 | 詹森药业有限公司 | 作为选择性雄激素受体调节剂(sarms)的吲哚、苯并呋喃和苯并噻吩衍生物 |
| TW200606129A (en) * | 2004-07-26 | 2006-02-16 | Chugai Pharmaceutical Co Ltd | Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same |
| CA2589667A1 (en) * | 2004-12-21 | 2006-06-29 | Eli Lilly And Company | Vitamin d receptor modulators |
| DK1836151T3 (da) * | 2004-12-21 | 2009-06-02 | Lilly Co Eli | D-vitamin-receptormodulatorer |
| CN102584512B (zh) * | 2011-12-22 | 2014-10-08 | 北京师范大学 | 一种一锅法合成苯并呋喃衍生物的方法 |
| US20240300939A1 (en) | 2021-06-14 | 2024-09-12 | Scorpion Therapeutics, Inc. | Urea derivatives which can be used to treat cancer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6218430B1 (en) * | 1998-08-24 | 2001-04-17 | Ligand Pharmaceuticals Incorporated | Vitamin D3 mimics |
| FR2801307B1 (fr) * | 1999-11-24 | 2002-12-06 | Galderma Res & Dev | Analogues de la vitamine d |
| SI1511740T1 (sl) * | 2002-05-29 | 2009-12-31 | Lilly Co Eli | Modulatorji vitamin d receptorja tipa fenil-tiofen |
| DE60326082D1 (de) * | 2002-11-22 | 2009-03-19 | Lilly Co Eli | Modulatoren von vitamin d rezeptoren |
| WO2004063348A2 (en) | 2003-01-10 | 2004-07-29 | Eli Lilly And Company | Vesicant treatment with phenyl-thiophene type vitamin d receptor modulators |
| EP1587906A2 (en) | 2003-01-10 | 2005-10-26 | Eli Lilly And Company | Vesicant treatment with phenyl-phenyl type vitamin d receptor modulators |
| CA2542650C (en) * | 2003-10-14 | 2013-04-23 | X-Ceptor Therapeutics, Inc. | Bridged ring structures as pharmaceutical agents |
| US7595345B2 (en) | 2003-11-20 | 2009-09-29 | Eli Lilly And Company | Vitamin D receptor modulators |
| WO2005051936A1 (en) | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Phenyl-furan compounds as vitamin d receptor modulators |
| WO2005051898A2 (en) | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Vitamin d receptor modulators |
| CA2544857A1 (en) | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Vitamin d receptor modulators |
| ES2291981T3 (es) * | 2003-11-20 | 2008-03-01 | Eli Lilly And Company | Moduladores del receptor de la vitamina d. |
| CA2589667A1 (en) | 2004-12-21 | 2006-06-29 | Eli Lilly And Company | Vitamin d receptor modulators |
| DK1836151T3 (da) | 2004-12-21 | 2009-06-02 | Lilly Co Eli | D-vitamin-receptormodulatorer |
-
2004
- 2004-11-16 CA CA002544857A patent/CA2544857A1/en not_active Abandoned
- 2004-11-16 WO PCT/US2004/035529 patent/WO2005051938A1/en not_active Ceased
- 2004-11-16 US US10/579,563 patent/US7579488B2/en not_active Expired - Fee Related
- 2004-11-16 EP EP04800486A patent/EP1687289A1/en not_active Withdrawn
- 2004-11-16 JP JP2006541192A patent/JP4717005B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007512327A5 (https=) | ||
| JP5149236B2 (ja) | 芳香族環を含む酸発生剤 | |
| Meek et al. | Oxygen and sulfur methylation of ambident p-toluenesulfinate anion | |
| TWI688571B (zh) | 化合物（四） | |
| GB2189783A (en) | Carbacyclin-cyclodextrin compositions | |
| JP2007513089A5 (https=) | ||
| CA1323364C (en) | Prostaglandins e and anti ulcer agents containing same | |
| US5376683A (en) | Δ8- and Δ9-prostaglandin derivatives, process for their production and their pharmaceutical use | |
| KR880007522A (ko) | 1, 1이치환된 시클로프로판 유도체 및 그의 제조 방법 | |
| CA2544501A1 (en) | Vitamin d receptor modulators | |
| JP4717006B2 (ja) | ビタミンｄ受容体モジュレータ | |
| CA2506891A1 (en) | Vitamin d receptor modulators | |
| JP4717005B2 (ja) | ビタミンｄ受容体モジュレータ | |
| MXPA06006901A (es) | Derivados de esteroides glicosilados con actividad antimigratoria. | |
| TW200305365A (en) | Chemical compounds | |
| JP2004501934A5 (https=) | ||
| JPS61143354A (ja) | コレカルシフエロール誘導体 | |
| CA2544517A1 (en) | Vitamin d receptor modulators | |
| WO2022156783A1 (zh) | 咪唑并吡啶类化合物的制备方法及其中间体 | |
| JP2008524260A5 (https=) | ||
| PL154330B1 (en) | Method of obtaining derivatives of 16-phenoxyprostatrienic acid | |
| AU620543B2 (en) | 6-oxoprostaglandin-e derivatives, process for their production and their pharmaceutical application | |
| CN102863472B (zh) | 考布他汀a-4类似物及其制备方法和在制备抗肿瘤药物中的应用 | |
| JP6687477B2 (ja) | エステル化合物の製造方法 | |
| JPH0688966B2 (ja) | プロスタグランジンｅ類およびそれを含む抗潰瘍剤 |